119 related articles for article (PubMed ID: 35164335)
1. Stability and Formulation of Erlotinib in Skin Creams.
Nguyen D; Secrétan PH; Cotteret C; Jacques-Gustave E; Greco C; Bodemer C; Schlatter J; Cisternino S
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164335
[TBL] [Abstract][Full Text] [Related]
2. Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma
Mangla B; Mittal P; Kumar P; Javed S; Ahsan W; Aggarwal G
Nanomedicine (Lond); 2024 Apr; 19(10):855-874. PubMed ID: 38440976
[TBL] [Abstract][Full Text] [Related]
3. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
[TBL] [Abstract][Full Text] [Related]
4. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Pang J; Xing H; Sun Y; Feng S; Wang S
Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
[TBL] [Abstract][Full Text] [Related]
5. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
[TBL] [Abstract][Full Text] [Related]
6. Interaction Characterization of a Tyrosine Kinase Inhibitor Erlotinib with a Model Transport Protein in the Presence of Quercetin: A Drug-Protein and Drug-Drug Interaction Investigation Using Multi-Spectroscopic and Computational Approaches.
Wani TA; Alanazi MM; Alsaif NA; Bakheit AH; Zargar S; Alsalami OM; Khan AA
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209054
[TBL] [Abstract][Full Text] [Related]
7. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
[TBL] [Abstract][Full Text] [Related]
8. Exploring the antioxidant potentiality of two food by-products into a topical cream: stability, in vitro and in vivo evaluation.
Rodrigues F; Sarmento B; Amaral MH; Oliveira MB
Drug Dev Ind Pharm; 2016; 42(6):880-9. PubMed ID: 26393899
[TBL] [Abstract][Full Text] [Related]
9. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of different co-antioxidants on the photochemical- and functional-stability of epigallocatechin-3-gallate in topical creams exposed to simulated sunlight.
Scalia S; Marchetti N; Bianchi A
Molecules; 2013 Jan; 18(1):574-87. PubMed ID: 23292326
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib complexation with randomly methylated
Erdoğar N; Akkın S; Varan G; Bilensoy E
Pharm Dev Technol; 2021 Sep; 26(7):797-806. PubMed ID: 34219578
[TBL] [Abstract][Full Text] [Related]
12. Electrochemical and theoretical study on interaction between erlotinib and DNA.
Jovanović M; Nikolic K; Čarapić M; Aleksić MM
J Pharm Biomed Anal; 2023 Sep; 234():115560. PubMed ID: 37421702
[TBL] [Abstract][Full Text] [Related]
13. UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction.
Maher HM; Alzoman NZ; Shehata SM; Abahussain AO
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Apr; 1049-1050():30-40. PubMed ID: 28260629
[TBL] [Abstract][Full Text] [Related]
14. Accelerate development of topical cream drug product using a common platform base formulation.
Modi D; Sharma H; Campbell G
Pharm Dev Technol; 2020 Jul; 25(6):767-778. PubMed ID: 32176856
[TBL] [Abstract][Full Text] [Related]
15. Development of a Topical Resveratrol Formulation for Commercial Applications Using Dendrimer Nanotechnology.
Pentek T; Newenhouse E; O'Brien B; Chauhan AS
Molecules; 2017 Jan; 22(1):. PubMed ID: 28098828
[TBL] [Abstract][Full Text] [Related]
16. Development of Oral Tablet Formulation Containing Erlotinib: Randomly Methylated-β-cyclodextrin Inclusion Complex Using Direct Compression Method.
Erdoğar N
Turk J Pharm Sci; 2021 Oct; 18(5):589-596. PubMed ID: 34719186
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies.
Maher HM; Alzoman NZ; Shehata SM
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():100-110. PubMed ID: 27336702
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
[TBL] [Abstract][Full Text] [Related]
19. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
Li Q; Liu Z; Kolli S; Wetz K; Griffith N; Poi MJ
Am J Health Syst Pharm; 2016 Sep; 73(17):1331-7. PubMed ID: 27543577
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
Shan F; Shao Z; Jiang S; Cheng Z
Cancer Med; 2016 Nov; 5(11):3166-3175. PubMed ID: 27726288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
